Use of some diabetes drugs linked to risk of acute gallbladder disease, FDA reports Medha Baranwal7 Sept 2022 11:15 AM ISTPatients who take glucagon-like peptide-1 receptor agonists for weight loss or management of diabetes may be at risk of acute gallbladder...
GLP-1 receptor agonist therapy has CV benefits in type 2 DM, shows survival time analysis Dr. Hiral patel1 Jun 2022 9:30 AM ISTUSA: Glucagon-like peptide (GLP)-1 receptor agonists may delay the incidence of major adverse cardiovascular events (MACE) Glucagon-like peptide...
GLP 1 Receptor Agonists to have better outcomes Than DPP4 Inhibitors Dr. Nandita Mohan14 March 2022 5:00 PM ISTA recent study suggests that the use of GLP-1 receptor agonists was associated with better outcomes compared with the use of DPP-4 inhibitors among...
Phentermine-topiramate and GLP-1 agonists best drugs for weight loss in obese: Lancet study Medha Baranwal29 Dec 2021 9:00 AM ISTChina: Phentermine-topiramate and GLP-1 receptor agonists seemed to be the best drugs for reducing weight in adults with overweight and obesity,...
SGLT2 inhibitors cause double weight loss than GLP-1 receptor agonists in diabetics: Study Hina Zahid3 July 2021 10:30 AM ISTAmong 72 patients, people using SGLT2 inhibitors experienced a median weight loss of more than 6 pounds, while those on GLP-1 receptor agonists lost a...
SGLT-2 inhibitors or GLP-1 receptor agonists use in type 2 diabetes: Expert Guidelines Medha Baranwal13 May 2021 7:00 PM ISTDelhi: An international panel including patients, clinicians, and methodologies has released risk-stratified recommendations concerning the use of...
Two groups of blood sugar control drugs significantly reduce CKD and CVD risk- AHA Dr. Kamal Kant Kohli29 Sept 2020 8:00 AM ISTDALLAS - Two newer groups of antidiabetic medications prescribed primarily for Type 2 diabetes treatment (SGLT2 inhibitors and GLP-1 receptor...
